Krystal Biotech, Inc. (KRYS)
$298.55
-1.44 (-0.48%)Delayed quote.
Price history
Daily close- Start
- $204.74
- Latest close
- $298.55
- Period change
- +45.82%
- Period low
- $204.10
- Period high
- $378.15
Key metrics
- Market cap
- $8.79B
- Volume
- 18.2K
- Average volume
- 355.5K
- 52-week range
- $203.17 – $382.54
- Beta
- 0.50
- Last dividend
- —
- EPS (TTM)
- $7.66
- P/E ratio
- 38.98
- Revenue (TTM)
- $470.02M
- Net income (TTM)
- $225.17M
- Total assets
- $1.59B
- Total debt
- $8.59M
- Cash and equivalents
- $462.84M
Key financials (trailing twelve months).
Company profile
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- CEO
- Krish S. Krishnan
- Employees
- 295
- Headquarters
- Pittsburgh, PA, US
- IPO date
- 2017-09-20
- Website
- https://www.krystalbio.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $389.13M | $290.51M | $50.70M |
| Gross profit | $360.36M | $270.45M | $47.60M |
| Operating income | $161.29M | $65.69M | -$109.73M |
| EBITDA | $196.02M | $109.91M | -$92.22M |
| Net income | $204.83M | $89.16M | $10.93M |
| Diluted EPS | $6.84 | $3.00 | $0.39 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $496.30M | $344.87M | $358.33M |
| Total assets | $1.33B | $1.06B | $818.36M |
| Total liabilities | $114.23M | $109.46M | $39.71M |
| Total debt | $9.34M | $7.26M | $8.09M |
| Shareholders’ equity | $1.22B | $946.38M | $778.64M |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $200.87M | $123.42M | -$88.80M |
| Capital expenditure | -$11.95M | -$4.24M | -$11.80M |
| Free cash flow | $188.91M | $119.18M | -$100.60M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $127.34M | $119.22M | $116.36M | $107.11M | $97.80M | $96.04M |
| Gross profit | $119.78M | $112.78M | $110.03M | $96.19M | $92.14M | $88.88M |
| Operating income | $71.14M | $58.42M | $53.69M | $44.44M | $41.37M | $39.31M |
| EBITDA | $81.83M | $67.64M | $63.17M | $39.61M | $49.58M | $48.32M |
| Net income | $63.07M | $54.77M | $55.93M | $51.40M | $79.36M | $38.33M |
| Diluted EPS | $2.05 | $1.79 | $1.83 | $1.70 | $2.66 | $1.29 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $462.84M | $427.74M | $501.31M | $496.30M | $392.60M | $353.83M |
| Total assets | $1.59B | $1.50B | $1.40B | $1.33B | $1.24B | $1.14B |
| Total liabilities | $150.47M | $141.52M | $120.24M | $114.23M | $102.22M | $97.75M |
| Total debt | $8.59M | $8.85M | $9.11M | $9.34M | $9.51M | $9.68M |
| Shareholders’ equity | $1.44B | $1.36B | $1.28B | $1.22B | $1.14B | $1.04B |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $91.25M | $74.79M | $80.38M | $77.51M | $39.66M | $52.73M |
| Capital expenditure | -$996.0K | -$3.56M | -$7.15M | -$2.14M | -$1.70M | -$1.90M |
| Free cash flow | $90.25M | $71.22M | $73.23M | $75.37M | $37.95M | $50.83M |